Levotuss

Levodropropizine, the active ingredient in Levotuss, is a cough suppressant presented as an oral formulation for systemic use. It is employed to alleviate dry, non‑productive cough in adults and children when prescribed by a healthcare professional. It acts peripherally on sensory nerve endings in the respiratory tract, reducing cough reflex sensitivity without central nervous system depression.

GNH USA supplies Levotuss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Levodropropizine is used as a peripheral antitussive to control cough associated with respiratory tract irritation.

- Dry cough: provides symptomatic relief by reducing the cough reflex. - Acute upper respiratory infection cough: alleviates coughing episodes during common colds. - Chronic non‑productive cough: helps manage persistent cough when other causes have been excluded.

Levodropropizine may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset reported by some patients. - Diarrhea: loose stools occurring occasionally. - Headache: transient head discomfort. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice in rare cases. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing levodropropizine, clinicians should consider the following precautions to ensure safe use.

- Pediatric use: dosage must be individualized and prescribed by a qualified healthcare professional. - Renal impairment: use with caution; dose adjustment may be required in severe renal dysfunction. - Hepatic impairment: monitor liver function and consider reduced dosing in patients with liver disease. - Concomitant CNS depressants: observe for additive sedation, although central effects are minimal. - Pregnancy and lactation: safety has not been established; avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Levodropropizine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Combined use with other peripheral antitussives: may increase risk of excessive cough suppression. - Co‑administration with strong CYP3A4 inhibitors (if metabolized via this pathway): may raise plasma levels and side‑effect risk.

Moderate Interactions (Monitor Closely): - Opioid cough suppressants (e.g., codeine): monitor for additive sedation or respiratory depression. - Antihistamines: may enhance antitussive effect, requiring observation. - Antidepressants affecting serotonin: watch for rare serotonin‑related effects.